Reactive Strength and Dynamic Rebound: A Drop Jump Index Comparison

March 13, 2026 updated by: Henrique Sousa, University Institute of Maia

Which Index Tells the Full Story? Comparing Reactive Strength and Dynamic Rebound Index in Drop Jump Performance

The stretch-shortening cycle (SSC) is a fundamental mechanism in explosive human movement, enabling musculotendinous units to store and release elastic energy, thereby allowing the body to produce higher forces and velocities with greater mechanical efficiency. Movements such as sprinting, jumping, hopping, and sudden changes of direction, which depend on rapid force application, are supported by an effective SSC. Because of this, identifying a simple and interpretable index of SSC function has long been a priority in both research and applied sport settings.

The Reactive Strength Index (RSI), most commonly defined as the ratio of jump height to ground contact time, has become the most widely used metric for quantifying SSC performance. However, this ratio presents notable methodological limitations: it combines variables of incompatible dimensions and is insensitive to drop height, thereby ignoring the eccentric load imposed on the musculotendinous system. The Dynamic Rebound Index (DRI), recently proposed as a dimensionless and mechanically grounded alternative, is calculated as DRI = (box height + jump height) / (9.8 × ground contact time²). Despite its theoretical advantages, a direct comparison between the RSI and DRI remains unexplored in the literature, which justifies the relevance of the present study.

This study aims to compare the RSI and the DRI in physically active adults of both sexes during the execution of the Drop Jump at four different drop heights (20, 30, 40, and 50 cm). The specific objectives are: (a) to characterize performance across the four height conditions; (b) to analyze differences between sexes in both indices; (c) to examine the effect of drop height on both indices; and (d) to explore the informative complementarity between the two indices.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
50

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Portugal
    • Porto District
      • Maia, Porto District, Portugal, 4475-690 Maia
        • University of Maia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18 years or older.
  • Physically active (engaging in regular physical activity at least 3 times per week - minimum of 180 min of physical activity).

Exclusion Criteria:

  • Any musculoskeletal injuries at the time of data collection.
  • Any medical condition that could compromise physical performance or safety during testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Drop Jump 20 cm
Participants perform 3 valid Drop Jump trials from a 20 cm drop height
Other: Drop Jump Protocol
Participants perform 3 valid Drop Jump trials at each of four drop heights (20, 30, 40, and 50 cm) in a randomized order, with 1 minute of rest between trials and 5 minutes between conditions. Jump height and ground contact time are recorded using a contact mat (ChronoJump, Boscosystem, Spain) for subsequent calculation of the RSI and DRI.
Other Names:
  • DJ
Experimental: Drop Jump 30 cm
Participants perform 3 valid Drop Jump trials from a 30 cm drop height
Other: Drop Jump Protocol
Participants perform 3 valid Drop Jump trials at each of four drop heights (20, 30, 40, and 50 cm) in a randomized order, with 1 minute of rest between trials and 5 minutes between conditions. Jump height and ground contact time are recorded using a contact mat (ChronoJump, Boscosystem, Spain) for subsequent calculation of the RSI and DRI.
Other Names:
  • DJ
Experimental: Drop Jump 40 cm
Participants perform 3 valid Drop Jump trials from a 40 cm drop height
Other: Drop Jump Protocol
Participants perform 3 valid Drop Jump trials at each of four drop heights (20, 30, 40, and 50 cm) in a randomized order, with 1 minute of rest between trials and 5 minutes between conditions. Jump height and ground contact time are recorded using a contact mat (ChronoJump, Boscosystem, Spain) for subsequent calculation of the RSI and DRI.
Other Names:
  • DJ
Experimental: Drop Jump 50 cm
Participants perform 3 valid Drop Jump trials from a 50 cm drop height
Other: Drop Jump Protocol
Participants perform 3 valid Drop Jump trials at each of four drop heights (20, 30, 40, and 50 cm) in a randomized order, with 1 minute of rest between trials and 5 minutes between conditions. Jump height and ground contact time are recorded using a contact mat (ChronoJump, Boscosystem, Spain) for subsequent calculation of the RSI and DRI.
Other Names:
  • DJ

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Reactive Strength Index (RSI)
Time Frame: Baseline
Calculated as RSI = jump height (m) / ground contact time (s), measured during the Drop Jump at four drop heights (20, 30, 40, and 50 cm).
Baseline
Dynamic Rebound Index (DRI)
Time Frame: Baseline
Calculated as DRI = (box height (m) + jump height (m)) / (9.8 × ground contact time² (s)), measured during the Drop Jump at four drop heights (20, 30, 40, and 50 cm)
Baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Jump Height
Time Frame: Baseline
Vertical jump height (m) recorded via contact mat during the Drop Jump.
Baseline
Ground Contact Time
Time Frame: Baseline
Time (s) spent in contact with the ground during the Drop Jump, recorded via contact mat.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Institute of Maia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 10, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 13, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 16, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 16, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 13, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DRI_HS_01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings